Education
About Us
Working with TipRanks
Follow Us
Esperion (GB:0IIM)
LSE:0IIM
0IIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $3.86
Previous CloseN/A
Volume10.92K
Average Volume (3M)40.97K
Market Cap
$171.22M
Enterprise ValueN/A
Total Cash (Recent Filing)$144.76M
Total Debt (Recent Filing)$297.60M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 05, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding198,199,460
10 Day Avg. Volume35,581
30 Day Avg. Volume40,970
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)-0.74
Price to Sales (P/S)0.00
P/FCF Ratio-12.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.31Price Target Upside593.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Esperion News
PremiumCompany Announcements
Esperion Therapeutics Reports Mixed Q1 2025 Results
PremiumCompany Announcements
Esperion Therapeutics Reports Strong Q1 2025 Earnings
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionEsperion is expanding its early-stage development pipeline with a new program targeting primary sclerosing cholangitis (PSC).
Revenue GrowthRevenue continues to grow, with a 41% increase in NEXLETOL/NEXLIZET U.S. product revenue driven by retail prescription growth.
Strategic PartnershipsEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada.
Bears Say
BA Franchise ConcernsThe pivot to liver diseases is likely raising concerns over Esperion's BA franchise.
Development RisksThe selection of PSC as an initial indication is seen as high risk due to developmental challenges and historical difficulties.
Financial ConcernsEsperion's current cash position is raising concerns about its ability to meet additional priorities and achieve sustained profitability.
Options Prices
Currently, No data available
---
Ownership Overview
1.75% Insiders
14.19%
Mutual Funds
0.61% Other Institutional Investors
73.50% Public Companies and Individual Investors
0IIM FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest share price was $0.70 and its highest was $3.85 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $171.22M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Aug 05, 2025 which is in 75 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 06, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.155 by -$0.055.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.15.
How many shares outstanding does Esperion have?
Esperion has 198,199,460 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.155. Following the earnings report the stock price went down -8.077%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in GB:0IIM
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.31 (593.41% Upside)
$6.31 (593.41% Upside)
Blogger Sentiment
Bullish
GB:0IIM Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
0IIM Company Deck
0IIM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong overall performance with significant revenue growth, expanded market access, and key pipeline advancements. However, challenges such as seasonal sales impacts and confusion due to policy changes were acknowledged. The highlights, particularly the revenue growth and guideline inclusion, outweigh the lowlights.Read More>0IIM Stock 12 Month Forecast
Average Price Target
$6.31
▲( 593.41% Upside)
Technical Analysis
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―